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Abstract
Background: Red blood cell (RBC) transfusions are essential in health care. The quality of rec-
ommendations included in clinical practice guidelines (CPG), regarding this intervention, has not
been systematically evaluated. This paper systematically assessed CPGs for RBC-transfusion, to
appraise their methodological quality, to explore changes in quality over time, and to assess the
consistency of the hemoglobin threshold (HT) recommendations.
Methods:We searched for CPGs that included recommendations of RBC-transfusion in generic
databases, compiler entities, registries, clearinghouses and guideline developers. Three reviewers
extracted data on CPGs characteristics and HT recommendations, independently appraised the
quality of the studies using AGREE II and resolved disagreements by consensus.
Results: We examined 16 CPGs. Mean scores (mean ± SD) were: scope and purpose (59.4% ±
19.8%), stakeholder involvement (43.2% ± 22.6%), rigor of development (50% ± 25%), clarity of
presentation (74.4% ± 12.6%), applicability (19.4% ± 18.8%), and editorial independence (41%
± 30%). Seven CPGs recommended a restrictive strategy for RBC transfusion; four CPGs gave
a guarded statement considering an HT of 7 g/dL, as safe to prescribe an RBC transfusion. Eight
CPGs did not provide an HT stating that RBC transfusions should not be prescribed by HT alone.
Conclusions: Only 3 out of the 16 evaluated CPGs were “recommended” by the independent
evaluators. Four domains “stakeholder involvement,” “rigor of development,” applicability,” and
“editorial independence” had serious shortcomings. Recommendations about the use of an HT for
RBC-transfusion were heterogeneous among guidelines. Greater efforts are needed to provide
high-quality CPGs in the RBC-transfusion practice.
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1 INTRODUCTION
Blood transfusion is the infusion of both soluble and cell-associated
forms like RBCs, white blood cells, and platelets into a recipient.1
A blood transfusion is an acute intervention, implemented to solve
life and health-threatening conditions on a short-term basis.2,3
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However, RBCs and other blood components therapies have been
associated with several adverse clinical events, and require physicians
to be fully informed of the risks and benefits.4,5 Several strategies
for preventing adverse events caused by RBC-transfusions have been
studied; however, their clinical effectiveness has not yet sufficiently
demonstrated.2,3,6–11
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About 85 million people are transfused annually, with considerable
variation in the use of RBC-transfusion practices worldwide.6 In spite
of the efforts to standardize transfusion practice, as the publication of
clinical practice guidelines, this variability in transfusion practices has
persisted. For instance, while some CPGs have included recommenda-
tions focused on hemoglobin concentration to guide RBC-transfusion,
other CPGs emphasize that transfusions should be provided in the
presence of anemia symptoms and should not be based on hemoglobin
concentration only.2,5,8,9
CPGs are defined as systematically developed statements to assist
practitioner and patient decisions about appropriate health care.12
International organizations have introduced and promote standards
for the development of CPG, such as the Institute ofMedicine (IOM),13
WorldHealthOrganization (WHO),14 National Institute forHealthand
Clinical Excellence (NICE),15 Scottish Intercollegiate Guideline Net-
work (SIGN),16 and Guidelines International Network (G-I-N).17 All
these efforts provide resources to assist guideline developers in pro-
ducing high-quality recommendations. Despite these initiatives, the
quality of the CPGs and the adherence to methodological guidelines
has been improved only lightly in the last decade.18–21
In the field of RBC-transfusion, a large body of clinical evidence has
been generated; resulting in the publication ofmany CPGs.22–40 These
CPGs face with inconsistent recommendations that potentially result
in confusion among clinicians, and the quality of the guidelines could
be put to question. For these reasons, there is a need to assess the
methodological quality of the CPGs in this field, to explain the variabil-
ity of the recommendations. We conducted a systematic assessment
of CPGs for RBC-transfusion, to appraisal their methodological quality
using AGREE II tool, and to explore changes in quality over time, and
to evaluate the consistency of hemoglobin concentration recommen-
dations to guide transfusion.
2 METHODS
2.1 Data search
We searched for CPGs that included recommendations of RBC-
transfusion in generic databases, compiler entities, registries, clear-
inghouses and guideline developers. We used free terms such as red
blood cell transfusion, blood transfusion, anemia, and erythrocyte cells
for these searches. For the MEDLINE search, via PubMed, we com-
bined MeSH terms (“blood transfusion,” “erythrocytes,” “Erythrocyte
Transfusion,” “blood component transfusion,” “anemia”) and free terms
(transfus* [tiab], transfusion requirements, RBC, RBCs, transfusion
strategy, blood loss, blood conservation, transfusion of RBCs, red cell
transfusion, management of anemia). Additionally, we used a series of
terms related to guidelines as: “practice guideline,” “consensus,” “devel-
opment conference,” and “guideline.” The search strategy and sources
are listed in Table 1.
2.2 Inclusion and exclusion criteria
We included (1) CPGs with recommendations related to hemoglobin
concentration to guide the RBC-transfusion; (2) CPGs that performed
a search in at least one database; and (3) CPGs published from
2006 until October 2017, in English or Spanish. We excluded (1) sec-
ondary publications like systematic reviews or meta-analyses and (2)
CPGs with recommendations about pediatric patients (<15 years) and
neonates.
2.3 Data collection
Two reviewers independently screened abstracts using the inclusion
criteria stated above. If the inclusion criteriamet, we retrieved the full-
text article and screened it to determine their eligibility. Two review-
ers independently extracted the following data from each CPG: title,
year, organization that developed the guideline, country of origin,
and source of funding. In the case of disagreement, a third reviewer
was consulted. One reviewer extracted the recommendation about
hemoglobin threshold to guide transfusion, and the individual studies
used to support the recommendation.
2.4 Quality assessment
Weused the AGREE instrument to evaluate the quality of the included
CPGs.41–44 This was developed primarily for guideline developers and
researchers, to outline and measure the core elements of guideline
development and implementation. The AGREE instrument (initially
AGREE I, now AGREE II) contains 23 items,41 spread over six domains:
scope and purpose, stakeholder involvement, rigor of development,
clarity and presentation, applicability, and editorial independence, in
addition to a final general item that evaluates the extent to which the
guideline can be recommended for use in practice. To evaluate the
items within the six domains, a 7-point Likert scale was used, rang-
ing from “strongly disagree” to “strongly agree.” For the overall assess-
ment, we used a 3-point scale ranging from “not recommended” to
“strongly recommended.” Three independent reviewers, with experi-
ence in CGs assessment, applied the AGREE II instrument. In the case
of disagreement, an agreementwas reached by consensus. In the event
of persistent disagreement, a fourth evaluator was consulted.
2.5 Statistical analysis
We performed a descriptive analysis of the CPGs according to the
country of origin, the type of organization that developed them,
the year of publication and the language of the CPGs. To establish
the quality of each CG, the standardized score was calculated as a per-
centage; this was obtained by adding all the individual points from the
items of a domain, and standardizing the total as a percentage of the
maximum possible score from that area: (score obtained − minimum
possible score)/(maximum possible score − minimum possible score)
× 100. Once the quality of each CG was established, it was compared
to the aforementioned descriptive variables. The degree of agreement
between the reviewers was assessed using an intraclass correlation
coefficient (ICC) with a 95% confidence interval (CI). Student's t-test
compared the scores between different variables (date of publication
and restrictive recommendations). For the analysis of the change in the
global scoreover time, thedateof publicationwas categorized into two
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TABLE 1 Searched sites for the identification of CPGs
Generic databases Websites
MEDLINE (PubMed) http://www.ncbi.nlm.nih.gov/pubmed/
TRIP database http://www.tripdatabase.com
Excelencia Clínica http://www.excelenciaclinica.net/
Compiler Entities, Registries, or Clearinghouses Websites
National Guidelines Clearinghouse http://www.guideline.gov/
Agency for Healthcare Research andQuality http://www.ahrq.gov/
Biblioteca de Guías de Práctica Clínica del SistemaNacional de Salud http://www.guiasalud.es
CanadianMedical Association Infobase: Clinical Practice Guidelines http://www.cma.ca
Guidelines Developers Websites
National Institute for Health and Care Excellence http://www.nice.org.uk
Scottish Intercollegiate Guidelines Network http://www.sign.ac.uk
NewZealand Guidelines Group http://www.nzgg.org.nz
Institute for Clinical Systems Improvement http://www.icsi.org
American College of Physicians http://www.acponline.org
International Society of Blood Transfusion http://www.isbtweb.org/
Asian Association of TransfusionMedicine (AATM) http://saatm.org/
Australian andNewZeland Society of Blood Transfusion http://www.anzsbt.org.au/
British Blood Transfusion Society https://www.bbts.org.uk/
American Red Cross http://www.redcross.org/
periods (2006–2011 and 2012–2015).Weused the statistical package
IBM SPSS (version 22).
3 RESULTS
3.1 Guideline characteristics
The search strategy provided 615 references after eliminating dupli-
cates. A review of the titles and abstracts identified 47 potentially eli-
gible CPGs. From the 47 examined CPGs, only 16 fulfilled the eligibil-
ity criteria and were included (Table 2).22–40 One of these guidelines
included four chapters that give the hemoglobin threshold recommen-
dation for different settings.34–37 Included guidelines were published
from 2008 to 2016. Six CPGswere from the United States,23,28,29,33,40
four from the United Kingdom,22,31,38,39 one with four chapters from
Australia,34–37 one from Canada,24 Finland,27 the Netherlands,26
Singapore,25 and Spain.30 Twelve documentswere developed by scien-
tific societies,22–24,27–33,39,40 and seven CPGs were developed by gov-
ernment agencies.25,26,34–38 Five of 16 included CPGs, focused solely
on RBC-transfusion,22–24,31,40 while there remaining 11 gave recom-
mendations on blood products in general.25–30,32–39
Eight guidelines gave recommendations for general medical
patients.24–27,30,35,38,40 The other 11 CPGs focused on specific popu-
lations: four on perioperative patients22,28,33,34; three on critically ill
patients23,31,36; two on obstetric patients37,39; one on patients with
heart disease32; and one on chronic kidney diseases patients.29
For the analysis of recommendations, each chapter of one of the
CPGs included,34–37 were considered separately due to differences
in hemoglobin threshold recommendation. Seven guidelines recom-
mended a restrictive strategy forRBC transfusion,30–33,36,38,40 defined
as the administration of blood transfusion when the hemoglobin
level falls below 7 g/dL. Four CPGs had a guarded statement con-
sidering a hemoglobin threshold of 7 g/dL, as safe to indicate
RBC transfusion.22,25,26,28 The remaining eight CPGs avoid giving a
hemoglobin threshold23,24,27,29,34,35,37,39 and state that RBC trans-
fusion should not be dictated by hemoglobin concentration alone
(Table 2).
Overall, 39 clinical trials supported these recommendations. The
references of included studies to base the recommendations were not
possible to obtain in two guidelines.24,27 Another twoCPGs supported
their recommendations in previously published guidelines37,39 (see
supplementary material for information about the evidence support-
ing recommendations). Only four guidelines used the Grading of Rec-
ommendations Assessment, Development and Evaluation (GRADE)
methodology to evaluate the quality of evidence and to grade the
strength of recommendations.30,31,38,40 One guideline used a mod-
ified version of GRADE,27 13 guidelines applied other methods to
determine the quality of the evidence,23–26,28,29,32–37,39 and 1 guide-
line did not explain the methodology used to assess the quality of
evidence.22
3.2 Quality assessment
The agreement between the three reviewers was high, with an ICC of
0.90 (95% CI: 0.81-0.96). Table 2 shows the standardized score of the
AGREE II tool by domain and by guideline, as well as the overall evalu-
ation. Additionally, Figure 1 shows the statistical summarized analysis
of the total standardized score by domain.
116 SIMANCAS-RACINES ET AL.
TABLE 2 CPG characteristics and hemoglobin threshold recommendations
Guideline Organization Year
Hemoglobin threshold
recommendation
Country and
language
Methods used to
assess the quality
and strength of the
evidence
Blood transfusion and
the anesthetists.
Red cell
transfusion22
The Association of
Anaesthetists of
Great Britain and
Ireland
2008 “The decision to transfuse should
always bemade on an individual
patient basis. Patients should not
normally be transfused if the
hemoglobin concentration
is>10 g/dL. A strong indication for
transfusion is a hemoglobin
concentration<7 g/dL″
(Perioperative patients)
UK/IR, English Grading system not
stated
Clinical practice
guideline: red blood
cell transfusion in
adult trauma and
critical care23
The Eastern
Association for
Surgery of Trauma
Practice
Management
Workgroup
2009 “The use of only Hb level as a ‘trigger’
for transfusion should be avoided.
A ‘restrictive’ strategy of RBC
transfusion (transfuse whenHb
7 g/dL) is as effective as a “liberal”
transfusion strategy (transfusion
whenHb 10 g/dL) in critically ill
patients with hemodynamically
stable anemia, except possibly in
patients with acutemyocardial
ischemia” (Critically ill patients)
USA, English Canadian and US
Preventative Task
Force grading
system
Guidelines for red
blood cell and
plasma transfusion
for adults and
children. updated24
Guidelines for
Canadian Clinical
Practice
Guidelines. Expert
Panel
2009 “Red blood cell transfusion should
not be dictated by a single
hemoglobin trigger but should be
based on a complete evaluation of
the patient including volume
status, tissue perfusion and
comorbid disease” (General
medical patients)
Canada,
English
Modified version of
the Canadian Task
Force on the
Periodic Health
Examination
grading system
Clinical blood
transfusion25
SingaporeMinistry of
Health
2011 “When hemoglobin>10 g/dL, there
is usually very little indication for
red cell transfusion.When
hemoglobin<7 g/dL, red cells
transfusionmay be beneficial
particularly in symptomatic
patients or ongoing blood loss is
expected” (General medical
patients)
Singapore,
English
Own rating scheme
used to assess the
quality of the
evidence
Blood transfusion
guideline26
Dutch Institute for
Healthcare
Improvement
2011 “The indication for administering
erythrocytes is based onmedical
factors and is aimed at treating or
preventing the symptoms of a lack
of oxygen transport capacity by
the blood. Consider a transfusion
if the following occurs at a
Hb< 4mmol/L: acute blood loss in
a healthy individual (ASA I)< 60
years, normovolemic, blood loss at
1 location” (General medical
patients)
The Nether-
lands,
English-
Dutch
Own rating scheme
used to assess the
quality of the
evidence
Blood transfusion:
indications,
administration, and
adverse reactions24
FinnishMedical
Society Duodecim
2011 “It is not possible to give single
hemoglobin (Hb) value as a trigger
for red cell transfusion since the
requirement for a transfusion is
based on anemia symptoms, the
patient's age, and the underlying
diseases (chronic or slowly
developing anemia)” (General
medical patients)
Finland,
English
Rating scheme
modified of GRADE
2011 by the EBM
Guidelines Editorial
Team
2011 update to The
Society of Thoracic
Surgeons and the
Society of
Cardiovascular
Anesthesiologists
Blood
Conservation
Clinical Practice
Guidelines28
The Society of
Thoracic Surgeons
and the Society of
Cardiovascular
Anesthesiologists
2011 “With hemoglobin levels below
6 g/dL, red blood cell transfusion is
reasonable since this can be
life-saving. Transfusion is
reasonable in most postoperative
patients whose hemoglobin is less
than 7 g/dL, but no high-level
evidence supports this
recommendation” (Perioperative
patients)
USA, English The assessment was
conducted
according to the
level of evidence
recommended by
the AHA/ACCF
Task Force on
Practice Guidelines
(Continues)
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TABLE 2 (Continued)
Guideline Organization Year
Hemoglobin threshold
recommendation
Country and
language
Methods used to
assess the quality
and strength of the
evidence
KDIGOClinical
Practice Guideline
for anemia in
chronic kidney
disease29
Kidney Disease:
Improving Global
Outcomes (KDIGO)
2012 “We suggest that the decision to
transfuse a CKD patient with
nonacute anemia should not be
based on any arbitrary Hb
threshold, but should be
determined by the occurrence of
symptoms caused by anemia”
(Chronic kidney diseases patients)
USA, English KDIGO grading
system
The “Seville”
document on
consensus on the
alternatives to
allogenic blood
transfusion30
The Spanish Societies
of Anesthesiology,
Critical Care
Medicine and
Coronary Units,
Hematology and
Hemotherapy,
Blood Transfusion
and Thrombosis
andHemostasis
2013 “Themajority of trauma, critical and
surgical patients can tolerate
hemoglobin levels of 70 g/L.
However, if they present acute
cardiological and/or central
nervous system involvement,
hemoglobin levels of at least
80 g/Lmay be required. In any
case, the decision to transfuse
should be individualized for each
patient” (General medical
patients)
Spain, Spanish GRADE 2008
Guidelines on the
management of
anemia and red cell
transfusion in adult
critically ill
patients31
British Committee for
Standards in
Haematology
2013 “A transfusion threshold of 70 g/L or
below, with a target Hb range of
70–90 g/L, should be the default
for all critically ill patients, unless
specific comorbidities or acute
illness-related factors modify
clinical decision-making”
(Critically ill patients)
UK, English GRADE 2008
Treatment of anemia
in patients with
heart disease: a
clinical practice
guideline from the
American College
of Physicians32
American College of
Physicians
2013 “ACP recommends using a restrictive
red blood cell transfusion strategy
(trigger hemoglobin threshold of 7
to 8 g/dL comparedwith higher
hemoglobin levels) in hospitalized
patients with coronary heart
disease”(Patients with heart
disease)
USA, English ACP's clinical practice
guidelines grading
system
Practice guidelines
for perioperative
blood
management—an
updated report by
the American
Society of
Anesthesiologists
Task Force on
Perioperative
Blood
Management33
American Society of
Anesthesiologists
2014 “A restrictive red blood cell
transfusion strategymay be safely
used to reduce transfusion
administration” (Perioperative
patients)
USA, English ASA grading system
TheNational Blood
Authority's Patient
BloodManagement
Guideline:Module
2—Perioperative34
National Blood
Authority Australia
2012 “RBC transfusion should not be
dictated by a hemoglobin ‘trigger’
alone but should be based on an
assessment of the patient's clinical
status” (Perioperative patients)
Australia,
English
National Blood
Authority scheme
TheNational Blood
Authority's Patient
BloodManagement
Guideline:Module
3—Medical35
National Blood
Authority Australia
2012 “RBC transfusion should not be
dictated by a Hb concentration
alone, but should also be based on
an assessment of the patient's
clinical status. Direct evidence is
not available in general medical
patients” (General medical
patients)
Australia,
English
National Blood
Authority scheme
TheNational Blood
Authority's Patient
BloodManagement
Guideline:Module
4—Critical Care36
National Blood
Authority Australia
2012 “In critically ill patients, a restrictive
transfusion strategy should be
employed” (Critically ill patients)
Australia,
English
National Blood
Authority scheme
(Continues)
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TABLE 2 (Continued)
Guideline Organization Year
Hemoglobin threshold
recommendation
Country and
language
Methods used to
assess the quality
and strength of the
evidence
TheNational Blood
Authority's Patient
BloodManagement
Guideline:Module
5—Obstetrics and
Maternity37
National Blood
Authority Australia
2015 “Inmaternity patients who are not
actively bleeding, RBC transfusion
should not be dictated by a Hb
concentration alone, but should
also be based on an assessment of
the patient's clinical status (eg, the
risk of further hemorrhage)”
(Obstetric patients)
Australia,
English
National Blood
Authority scheme
Blood Transfusion
NICE guideline38
National Institute for
Health and Care
Excellence
2015 “Use restrictive red blood cell
transfusion thresholds for
patients who need red blood cell
transfusions andwho do not: have
major hemorrhage, or have the
acute coronary syndrome, or need
regular blood transfusions for
chronic anemia” (General medical
patients)
UK, English GRADE
Blood transfusion in
obstetrics39
Royal College of
Obstetricians &
Gynaecologists
2015 “There are no firm criteria for
initiating red cell transfusion. The
decision to provide blood
transfusion should bemade on
clinical and hematological
grounds” (Obstetric patients)
UK, English Scheme using Royal
College of
Obstetricians and
Gynaecologists for
grading
recommendations
Clinical practice
guidelines from the
AABB: red blood
cell transfusion
thresholds and
storage40
American Association
of Blood Banks
2016 “The AABB recommends a
restrictive RBC transfusion
threshold in which the transfusion
is not indicated until the
hemoglobin level is 7 g/dL for
hospitalized adult patients who
are hemodynamically stable,
including critically ill patients,
rather than a liberal threshold
when the hemoglobin level is
10 g/dL” (General medical
patients)
USA, English GRADE
F IGURE 1 Distribution of the standardized domain scores for 16
CPGs. The top and bottom of the box represent the 75th (Q3) and
25th percentile (Q1), respectively, and the band near themiddle of the
box indicates the 50th percentile (median). The upper and lower ends
of the whisker represent Q3+ 1.5× (interquartile range), andQ1-1.5×
(interquartile range), respectively
3.2.1 Domain 1: scope and purpose
This domain focuses on the general goal of the CPGs, considering the
health condition, and the specific population for applying the guideline.
The average score was 59.4% (median = 62% and a range from 22.2%
to 87%; Figure 1). Five CPGs (31%) scored above 70%.23,30,32,34,38 See
Table 2 for details about Domain 1.
3.2.2 Domain 2: stakeholder involvement
This domain assesses the working group that developed the CPGs, the
involvement of stakeholders, and potential users. The average score
was 43.2% (median = 40% and a range from 13% to 78%; Figure 1).
Only three CPGs (18.7%) scored more than 70 on this domain.26,29,38
See Table 3 for details about Domain 2.
3.2.3 Domain 3: rigor of development
This domain addresses the process used to identify and summarize
the evidence, the methodology to formulate recommendations, and
their updates. The average score was 50% (median = 53% and a range
from 9% to 87%; Figure 1). Four CPGs (25%) scored above 70% on this
domain.26,29,34,38 See Table 3 for details about Domain 3.
3.2.4 Domain 4: clarity and presentation
This domain focuses on thewording, the structure, and the general for-
mat of the CPGs. The average score was 74.4% (median = 75% and a
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range from 51% to 92.6%; Figure 1). Nine CPGs (56.2%) scored above
70% on this domain.23,25,26,29–32,34,38 This domain scored the high-
est among the six domains included in the AGREE II instrument. See
Table 3 for details about Domain 4.
3.2.5 Domain 5: applicability
This domain considers the barriers and facilitators for the implemen-
tation of the CPGs, including aspects of resources and adherence to
the recommendations. The average score was 19.4% (median = 14%
and a range from0% to 54.2%; Figure 1). Thiswas the lowest evaluated
domain for all the CPGs, and none of the included CPGs scored above
70% on this domain. See Table 3 for details about Domain 5.
3.2.6 Domain 6: editorial independence
This domain assesses if funding sources influenced recommenda-
tions. The average score was 41% (median = 40% and a range from
0% to 86%; Figure 1). Four CPGs (25%) scored above 70% on this
domain.29,32,34,38 See Table 3 for details about Domain 6.
3.2.7 Overall assessment
Three out of the 16 evaluated CPGs (18.7%) were “recommended”
by the independent evaluators,29,34,38 6 CPGs (37.5%) were “recom-
mended with modifications,”23,26,28,30,32,40 and 7 CPGs (43.7%) were
“not recommended” (see Table 3).22,24,25,27,31,33,39 The three “recom-
mended” CPGs scored ≥ 70% in the “rigor of development” domain.
The seven CPGs (18.7%) “not recommended”22,24,25,27,31,33,39 by eval-
uators had scores below 70% in five of the six reported domains (see
Table 3).
We did not find statistically significant differences in the AGREE II
global score between CPGs published in 2006-2011 and those pub-
lished in the period 2012–2015 (P = 0.49). Additionally, those CPGs
recommending restrictive strategies scored similarly in the rigor of
development domain, as those that did not recommend a specific
threshold (P= 0.92).
4 DISCUSSION
4.1 Summary of themain finding
In our review, we found 16 CPGs that met the eligibility criteria.22–40
In the overall CPGs’ assessment, only 3 out of the 16 evaluated CPGs
(18.7%) were “recommended” by the independent evaluators,29,34,38 6
CPGs (37.5%) were “recommended with modifications,”23,26,28,30,32,40
and 7 CPGs (43.7%) were “not recommended.”22,24,25,27,31,33,39
Most of the CPGs did not describe the literature search and
selection methods, and they were ambiguous regarding how the
evidence was appraized and whether or not the recommenda-
tions were truly evidence-based. The domains with the highest
scores were “clarity and presentation” and “scope and purpose,”
and the domains with the lowest scores were “applicability” and
“editorial independence” (see Table 3 and Figure 1). Only four
CGs26,29,34,38 scored ≥ 70% in the domain “rigor of development,”
which was considered one of the most critical domains, as it refers to
methodological aspects concerning how the recommendations were
developed.
In the analyzed CPGs, the use of a hemoglobin threshold for RBC-
transfusion was variable. Some guidelines recommended restrictive
strategies, and other CPGs avoided using a hemoglobin threshold, on
the basis that RBC-transfusion should not be dictated by hemoglobin
concentration alone. However, when the score in the rigor of devel-
opment domain, of the CPGs recommending restrictive strategies, as
compared with the CPGs that avoid giving a hemoglobin threshold,
we did not find statistically significant differences. Therefore, the vari-
ability in recommendations cannot be explained by differences in this
domain (P= 0.92).
Finally, our study could not demonstrate statistical differences over
time in the global score of CPGs quality (published in 2006–2011 ver-
sus 2012-2016; P= 0.49). However, we believe that the low number of
included CPGs did not allow an adequate evaluation of the variability
in the quality of RBC-transfusion CGs over time.
4.2 The context of this reviewwith other literature
This review represents the first systematic assessment of the quality
of clinical practice guidelines focused on red blood cell transfusion rec-
ommendations. Consistently with previous CPG evaluations in other
clinical areas,45–48 the domains with the highest scores were “clarity
of presentation” and “scope and purpose,” whereas the domains with
the lowest scores were “stakeholder involvement,” “editorial indepen-
dence,” and “applicability.” The lowest scores related to the “applicabil-
ity” domain can be related to the belief that the activity of formulating
recommendations was separated from the implementation processes.
Our results for the domains were similar to those of previous system-
atic assessment done by our group, that included the evaluation of 626
CPGs.19 Specifically, in the “rigor of development” domain our review
found low quality, with an average of 46.3% compared to 68% in other
similar reviews.19
4.3 Strengths and limitations
Our systematic assessment has some limitations. First, although a
robust set of search criteria was formulated and tested prior to full
guideline identification, some CPGs might not have been adequately
indexed as they were only used for institutional purposes, so we failed
in their identification. We think that the quality of the CPGs not
indexed in biomedical databases is probably lower compared to those
indexed. Second, there is also a potential risk of selection bias because
we included only studies that had been published in English or Span-
ish. To this extent, our assessment could be overestimating the qual-
ity of CPGs in RBC-transfusion. Third, the AGREE II41–44 instrument
has undergone some revisions since the development of the original
AGREE instrument.41 A 7-point scale is used instead of a 4-point scale
for evaluating the items in the domains. This may have been a limita-
tion in assessing the quality of the CPGs because the only well-defined
points in the scale are 1 and 7. We found that the evaluators had dif-
ficulty in distinguishing between 3, 4, and 5 Likert values, which may
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have introduced a potential risk of reporting bias. However, the agree-
ment among reviewers using the AGREE II instrument was high, with
an ICC of 0.97.
On the other hand, we recognize some strengths of this systematic
assessment. First, we are the first to assess the quality of development
of clinical practice guidelines focused on red blood cell transfusion
recommendations using methodological instruments that are widely
recognized and accepted. Second, the uses of extensive search strate-
gies, covering both indexed and gray literature and the use of expert
appraisers who completed training and calibration to assess the qual-
ity of CPGs.
In conclusion, our findings show that much remains to be done to
reach excellence in the area of CPGs on RBC-transfusion. Only three
out of the 16 evaluated CPGs were “recommended” by the indepen-
dent evaluators. Four domains (“stakeholder involvement,” “rigor of
development,” “applicability,” and “editorial independence”) had seri-
ous shortcomings. The domains: “scope and purpose” and “clarity of
presentation” were themore precisely reported.
Moreover, our study could not demonstrate statistical differences
over time in the global score of CPGs quality (published in 2006-
2011 versus 2012-2016; P = 0.49). Also, the recommendations about
hemoglobin threshold for RBC-transfusion was variable among the
CPGs analyzed.
Clinical practice guidelines users should be aware of the low
quality reported in this study. Meanwhile, developers should adhere
to rigorous methods, like those provided in handbooks from insti-
tutions, such as the Scottish Intercollegiate Guidelines Network
(SIGN) or the National Institute for Health and Care Excellence
(NICE).15 Additionally, guideline developers should use check-
lists to optimize methods for the development and reporting of
CPG, such as the GIN-McMaster Guideline Development Checklist
(GDC)49,50 and AGREE II,42–44 respectively. Moreover, to improve
communication among users and developers, GRADE methodol-
ogy is highly recommended, as it is a widely implemented rigorous
system.
Regarding research strategies, additional efforts should be made
to develop and consolidate networks, to improve the evaluation
and synthesis of the available evidence in the RBC-transfusion field.
Researchers, who wish to identify knowledge gaps, and policy-
makers, looking to endorse adequate CPG development, should
work together to ensure the adherence to recommendations related
to RBC-transfusion, and minimize the heterogeneity in clinical
practice.
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